PT3142701T - Novo tratamento - Google Patents
Novo tratamentoInfo
- Publication number
- PT3142701T PT3142701T PT15724354T PT15724354T PT3142701T PT 3142701 T PT3142701 T PT 3142701T PT 15724354 T PT15724354 T PT 15724354T PT 15724354 T PT15724354 T PT 15724354T PT 3142701 T PT3142701 T PT 3142701T
- Authority
- PT
- Portugal
- Prior art keywords
- new treatment
- treatment
- new
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1408384.4A GB201408384D0 (en) | 2014-05-12 | 2014-05-12 | New treatment |
| GBGB1417719.0A GB201417719D0 (en) | 2014-10-07 | 2014-10-07 | New treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3142701T true PT3142701T (pt) | 2018-10-18 |
Family
ID=53264683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT15724354T PT3142701T (pt) | 2014-05-12 | 2015-05-11 | Novo tratamento |
| PT171744469T PT3231444T (pt) | 2014-05-12 | 2015-05-11 | Novo tratamento |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT171744469T PT3231444T (pt) | 2014-05-12 | 2015-05-11 | Novo tratamento |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10864213B2 (pt) |
| EP (2) | EP3142701B1 (pt) |
| AU (1) | AU2015261239B2 (pt) |
| CA (1) | CA2948620C (pt) |
| CY (2) | CY1120550T1 (pt) |
| DK (2) | DK3142701T3 (pt) |
| ES (2) | ES2773142T3 (pt) |
| HU (1) | HUE048020T2 (pt) |
| IL (1) | IL248856B (pt) |
| MX (1) | MX2016014756A (pt) |
| PL (2) | PL3142701T3 (pt) |
| PT (2) | PT3142701T (pt) |
| RU (1) | RU2688191C2 (pt) |
| SI (2) | SI3142701T1 (pt) |
| WO (1) | WO2015173551A1 (pt) |
| ZA (1) | ZA201607705B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3219705T3 (pl) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CN105130948A (zh) | 2010-04-22 | 2015-12-09 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
| RS57476B9 (sr) | 2014-04-15 | 2021-10-29 | Vertex Pharma | Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze |
| WO2015173551A1 (en) | 2014-05-12 | 2015-11-19 | Verona Pharma Plc | New treatment |
| NZ729796A (en) | 2014-09-15 | 2024-01-26 | Verona Pharma Plc | Liquid inhalation formulation comprising rpl554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| IT201700085714A1 (it) * | 2017-07-26 | 2019-01-26 | Luigi Maiuri | Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB201911517D0 (en) * | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| CA3160752A1 (en) * | 2019-12-26 | 2021-07-01 | Preston E. BRATCHER | Methods of treating cystic fibrosis transmembrane conductance regulator (cftr) dysfunction |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE455946B (sv) | 1986-10-20 | 1988-08-22 | Trion Forskning & Utveckling | Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| WO1992022286A1 (en) | 1991-06-12 | 1992-12-23 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
| WO1993011747A1 (en) | 1991-12-18 | 1993-06-24 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| NZ507619A (en) | 1998-04-18 | 2003-05-30 | Glaxo Group Ltd | Pharmaceutical aerosol formulation with liquefied propellant gas |
| GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| DE60005493T2 (de) | 1999-03-31 | 2004-07-01 | Vernalis Ltd., Wokingham | Pyrimido[6,1-a]isochinolinonderivate |
| US7090831B1 (en) | 1999-04-14 | 2006-08-15 | Smithkline Beecham Corporation | Pharmaceutical aerosol formulation |
| RS53895B1 (en) | 2004-06-24 | 2015-08-31 | Vertex Pharmaceuticals Incorporated | ATP-BINDING CASSETTE TRANSPORT MODULATORS |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| CN108117546A (zh) | 2008-11-06 | 2018-06-05 | 弗特克斯药品有限公司 | Atp-结合盒转运蛋白调节剂 |
| CN105175479B (zh) | 2009-09-11 | 2017-06-09 | 奇斯药制品公司 | 异噁唑烷衍生物 |
| EP2603509B1 (en) * | 2010-08-09 | 2014-06-18 | Verona Pharma PLC | Crystalline form of pyrimido[6,1-a] isoquinolin-4-one compound |
| BR112013012160A2 (pt) | 2010-11-26 | 2019-09-24 | Chiesi Farm Spa | compostos, composição farmacêutica, uso de um composto e dispositivo |
| WO2012107364A1 (en) * | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
| EP2744493A1 (en) * | 2011-08-18 | 2014-06-25 | Shire AG | Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy |
| EP2819670A1 (en) * | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| CN105229547A (zh) | 2013-03-14 | 2016-01-06 | 林肯环球股份有限公司 | 导出或者使用针对外部系统的焊接定序器数据的系统和方法 |
| HUE037275T2 (hu) | 2013-03-15 | 2018-08-28 | Verona Pharma Plc | Gyógyszer-kombináció |
| WO2015173551A1 (en) | 2014-05-12 | 2015-11-19 | Verona Pharma Plc | New treatment |
| NZ729796A (en) | 2014-09-15 | 2024-01-26 | Verona Pharma Plc | Liquid inhalation formulation comprising rpl554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB202002786D0 (en) | 2020-02-27 | 2020-04-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
-
2015
- 2015-05-11 WO PCT/GB2015/051377 patent/WO2015173551A1/en active Application Filing
- 2015-05-11 PL PL15724354T patent/PL3142701T3/pl unknown
- 2015-05-11 DK DK15724354.4T patent/DK3142701T3/en active
- 2015-05-11 ES ES17174446T patent/ES2773142T3/es active Active
- 2015-05-11 AU AU2015261239A patent/AU2015261239B2/en active Active
- 2015-05-11 DK DK17174446.9T patent/DK3231444T3/da active
- 2015-05-11 EP EP15724354.4A patent/EP3142701B1/en active Active
- 2015-05-11 SI SI201530328T patent/SI3142701T1/en unknown
- 2015-05-11 EP EP17174446.9A patent/EP3231444B1/en active Active
- 2015-05-11 PT PT15724354T patent/PT3142701T/pt unknown
- 2015-05-11 ES ES15724354.4T patent/ES2682105T3/es active Active
- 2015-05-11 PL PL17174446T patent/PL3231444T3/pl unknown
- 2015-05-11 SI SI201531105T patent/SI3231444T1/sl unknown
- 2015-05-11 PT PT171744469T patent/PT3231444T/pt unknown
- 2015-05-11 US US15/310,693 patent/US10864213B2/en active Active
- 2015-05-11 HU HUE17174446A patent/HUE048020T2/hu unknown
- 2015-05-11 RU RU2016148447A patent/RU2688191C2/ru active
- 2015-05-11 CA CA2948620A patent/CA2948620C/en active Active
- 2015-05-11 MX MX2016014756A patent/MX2016014756A/es active IP Right Grant
-
2016
- 2016-11-08 ZA ZA2016/07705A patent/ZA201607705B/en unknown
- 2016-11-09 IL IL248856A patent/IL248856B/en active IP Right Grant
-
2018
- 2018-08-09 CY CY20181100831T patent/CY1120550T1/el unknown
-
2020
- 2020-02-19 CY CY20201100153T patent/CY1122748T1/el unknown
- 2020-11-16 US US17/099,598 patent/US11759467B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI3231444T1 (sl) | 2020-04-30 |
| RU2016148447A3 (pt) | 2018-12-27 |
| SI3142701T1 (en) | 2018-08-31 |
| CY1120550T1 (el) | 2019-07-10 |
| DK3142701T3 (en) | 2018-08-13 |
| EP3231444A1 (en) | 2017-10-18 |
| ES2773142T3 (es) | 2020-07-09 |
| US10864213B2 (en) | 2020-12-15 |
| CA2948620C (en) | 2023-01-24 |
| ZA201607705B (en) | 2020-05-27 |
| PL3231444T3 (pl) | 2020-05-18 |
| IL248856A0 (en) | 2017-01-31 |
| CY1122748T1 (el) | 2021-03-12 |
| PL3142701T3 (pl) | 2018-11-30 |
| HUE048020T2 (hu) | 2020-05-28 |
| EP3142701A1 (en) | 2017-03-22 |
| IL248856B (en) | 2020-07-30 |
| DK3231444T3 (da) | 2020-03-16 |
| US20210106585A1 (en) | 2021-04-15 |
| RU2688191C2 (ru) | 2019-05-21 |
| PT3231444T (pt) | 2020-03-05 |
| AU2015261239B2 (en) | 2020-02-27 |
| EP3231444B1 (en) | 2019-12-18 |
| WO2015173551A1 (en) | 2015-11-19 |
| RU2016148447A (ru) | 2018-06-19 |
| US20170112839A1 (en) | 2017-04-27 |
| MX2016014756A (es) | 2017-03-23 |
| US11759467B2 (en) | 2023-09-19 |
| AU2015261239A1 (en) | 2016-12-01 |
| CA2948620A1 (en) | 2015-11-19 |
| ES2682105T3 (es) | 2018-09-18 |
| EP3142701B1 (en) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3132034T (pt) | Terapêutica | |
| IL248856A0 (en) | New treatment | |
| GB201522243D0 (en) | Treatment | |
| GB201401430D0 (en) | Treatment process | |
| GB201502137D0 (en) | Treatment | |
| GB201410216D0 (en) | Therapeutic | |
| SG11201601030VA (en) | Massager | |
| GB201406989D0 (en) | Novel treatments | |
| GB201519450D0 (en) | Novel treatment | |
| PT3099317T (pt) | Tripsina de bacalhau para utilização no tratamento de infeções microbianas num indivíduo com imunodeficiência | |
| GB201412011D0 (en) | Treatments | |
| GB201510637D0 (en) | Therapeutic | |
| GB201508841D0 (en) | Treatment | |
| GB201411027D0 (en) | Treatment | |
| GB201503008D0 (en) | Treatment | |
| GB201414542D0 (en) | Novel therapy | |
| GB201417719D0 (en) | New treatment | |
| GB201408384D0 (en) | New treatment | |
| GB201518349D0 (en) | Treatment | |
| GB201413317D0 (en) | Atheroscierosis treatment | |
| GB201515739D0 (en) | Treatment | |
| GB201412411D0 (en) | Treatment | |
| GB201412410D0 (en) | Treatment | |
| GB201514008D0 (en) | Treatment | |
| GB201400238D0 (en) | Treatment |